| Bioactivity | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis[1]. |
| Target | complement protein C5 |
| Invitro | Ravulizumab 与 C5 高亲和力结合并抑制 C5a 和 C5b 的形成，从而防止免疫激活和溶血[1]。 |
| Name | Ravulizumab |
| CAS | 1803171-55-2 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lee JW, et, al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530-539. |